Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Neutral
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
N/A
Address
107 Rundle Street Kent Town, South Australia (SA) 5067
Description
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. It operates through the following segments: Faster Growing (iTrack), Emerging (2RT), and Core Ophthalmic Mark (Lasers and Ultrasounds). The iTrack segment offers catheter device that dilates the ocular structures compromised by glaucoma. The 2RT segment includes patent-protected with significant lead on competition and a per-use recurring fee business model. The Lasers and Ultrasounds segment represents testimony to the strength of the Ellex brand and was driven by growth in sales of the high-margin Ellex Tango and Ellex Tango Reflex glaucoma lasers. The company was founded by Giuseppe Canala and Victor Previn in 1985 and is headquartered in Kent Town, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.09 - 0.22
Trade Value (12mth)
AU$12,959.00
1 week
0%
1 month
-6.45%
YTD
-17.14%
1 year
-30.95%
All time high
0.71
EPS 3 yr Growth
-27.50%
EBITDA Margin
-23.00%
Operating Cashflow
-$6m
Free Cash Flow Return
-26.60%
ROIC
-39.80%
Interest Coverage
-42.60
Quick Ratio
1.80
Shares on Issue (Fully Dilluted)
280m
HALO Sector
Healthcare
Next Company Report Date
02-Sep-26
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
27 August 25 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
27 August 25 |
Full year Financial Results
×
Full year Financial Results |
27 August 25 |
Appendix 4G and Corporate Governance statement
×
Appendix 4G and Corporate Governance statement |
27 August 25 |
Investor Presentation 30 June 2025 Results
×
Investor Presentation 30 June 2025 Results |
05 August 25 |
Appendix 3Y Spurling
×
Appendix 3Y Spurling |
04 August 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
04 August 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
31 July 25 |
Investor Webinar
×
Investor Webinar |
29 July 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 July 25 |
Amended Quarterly Activities/Appendix 4C Cash Flow
×
Amended Quarterly Activities/Appendix 4C Cash Flow |
28 July 25 |
Investor Webinar Thursday 31 July @ 11.30 am AEST
×
Investor Webinar Thursday 31 July @ 11.30 am AEST |
22 July 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
22 July 25 |
Notification regarding unquoted securities - EYE
×
Notification regarding unquoted securities - EYE |
08 July 25 |
Record Revenues for FY25
×
Record Revenues for FY25 |
08 July 25 |
Investor Webinar
×
Investor Webinar |
04 July 25 |
Investor Webinar Wednesday 9 July @ 11.30 am AEST
×
Investor Webinar Wednesday 9 July @ 11.30 am AEST |
20 June 25 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
21 May 25 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
09 May 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
06 May 25 |
March Quarterly Webinar Presentation
×
March Quarterly Webinar Presentation |
05 May 25 |
Application for quotation of securities - EYE
×
Application for quotation of securities - EYE |
05 May 25 |
Cleansing Notice
×
Cleansing Notice |
02 May 25 |
Notification of cessation of securities - EYE
×
Notification of cessation of securities - EYE |
30 April 25 |
Investor Webinar Tuesday 6 May @2.30 PM AEST
×
Investor Webinar Tuesday 6 May @2.30 PM AEST |
29 April 25 |
March 2025 Quarterly Activities Report and Appendix 4C
×
March 2025 Quarterly Activities Report and Appendix 4C |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.